SEMA7A-ITGB1 axis plays pivotal roles for EGFR-TKI resistance in human EGFR mutant lung cancer

被引：0
|
作者：
Kinehara, Yuhei [1 ,2 ]
Nagatomo, Izumi [1 ]
Kijima, Takashi [3 ]
Kumanogoh, Atsushi [1 ]
机构：
[1] Osaka Univ, Dept Resp Med Immunol, Suita, Osaka, Japan
[2] Hosp Nissay, Osaka, Japan
[3] Hyogo Coll Med, Div Resp Med, Nishinomiya, Hyogo, Japan
来源：
CANCER SCIENCE | 2018年 / 109卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
J-3044
引用
收藏
页码：1185 / 1185
页数：1
相关论文
共 50 条
  • [21] Recent advances in the development of mutant-selective EGFR inhibitors for non-small cell lung cancer patients with EGFR-TKI resistance
    Luo, Yung-Hung
    Chen, Yuh-Min
    TRANSLATIONAL LUNG CANCER RESEARCH, 2014, 3 (06) : 368 - 369
  • [22] Inhibition of AXL and Mcl-1 Contributes to Eradicating Tolerance to EGFR-TKI Lazertinib in Lung Cancer Cells Expressing Mutant EGFR
    Matsui, Y.
    Yamada, T.
    Takayama, K.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S342 - S342
  • [23] Unraveling EGFR-TKI resistance in lung cancer with high PD-L1 or TMB in EGFR-sensitive mutations
    Ding, Wuwu
    Yang, Pengmin
    Zhao, Xiaokai
    Wang, Xiaozhi
    Liu, Huaqing
    Su, Qing
    Wang, Xintao
    Li, Jieyi
    Gong, Ziying
    Zhang, Daoyun
    Wang, Xinwei
    RESPIRATORY RESEARCH, 2024, 25 (01)
  • [24] Unraveling EGFR-TKI resistance in lung cancer with high PD-L1 or TMB in EGFR-sensitive mutations
    Wuwu Ding
    Pengmin Yang
    Xiaokai Zhao
    Xiaozhi Wang
    Huaqing Liu
    Qing Su
    Xintao Wang
    Jieyi Li
    Ziying Gong
    Daoyun Zhang
    Xinwei Wang
    Respiratory Research, 25
  • [25] Novel two mechanisms for acquired EGFR-TKI resistance in lung cancer cells harboring EGFR activating mutation
    Izumi, Hiroto
    Kanda, Rina
    Murakami, Yuichi
    Morimoto, Yasuo
    Ono, Mayumi
    EUROPEAN RESPIRATORY JOURNAL, 2014, 44
  • [26] Combination of EGFR-TKI and Chemotherapy Versus EGFR-TKI Monotherapy as Neoadjuvant Treatment of Stage III-N2 EGFR-Mutant Non-Small Cell Lung Cancer
    Xu, Yingqi
    Ji, Hao
    Zhang, Yidan
    Xiong, Liwen
    Han, Baohui
    Zhong, Hua
    Xu, Jianlin
    Zhong, Runbo
    ONCOLOGIST, 2024, 29 (07): : e932 - e940
  • [27] Novel two mechanisms for acquired EGFR-TKI resistance in lung cancer cells harboring EGFR activating mutation
    Izumi, Hiroto
    Kanda, Rina
    Murakami, Yuichi
    Morimoto, Yasuo
    Ono, Mayumi
    EUROPEAN RESPIRATORY JOURNAL, 2014, 44
  • [28] Analysis of primary and secondary EGFR-TKI resistance mutations evolution in 835 EGFR-mutant Chinese lung cancers.
    Dong, Xiaorong
    Zeng, Dongqiang
    Liu, Xinyi
    Huang, Mengli
    CANCER RESEARCH, 2021, 81 (13)
  • [29] Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers
    Yu, Helena A.
    Arcila, Maria E.
    Rekhtman, Natasha
    Sima, Camelia S.
    Zakowski, Maureen F.
    Pao, William
    Kris, Mark G.
    Miller, Vincent A.
    Ladanyi, Marc
    Riely, Gregory J.
    CLINICAL CANCER RESEARCH, 2013, 19 (08) : 2240 - 2247
  • [30] PD-L1 confers primary resistance to EGFR-TKI in EGFR mutant non-small cell lung cancer via inducing EMT phenotype
    Zhang, Y.
    Liu, T.
    Zeng, Y.
    Zhu, J.
    Du, W.
    Liu, Z.
    Huang, J-A.
    ANNALS OF ONCOLOGY, 2019, 30
12345